Aim We aim to evaluate whether assessments in the newly diagnosed pathway identify additional care needs in higher risk patients. Methods An evaluation was carried out of our new patient database. Individuals who had the prognostic indicator performed (n=52) were included in the evaluation. Results Patients in the high risk groups were found to be older and more cognitively impaired than lower risk patients (p<0.05). MOCA scores negatively correlated with NMS Quest (r=À0.44, p<0.001) and p<0.001) suggesting as cognition becomes impaired, NMS burden increases, and quality of life is reduced. Conclusions Additional care needs were identified in high-risk patients. These findings highlight additional resources are required in this patient cohort to ensure needs are met. Objective To evaluate the utility of the Parkinson's Kinetigraph (PKG™) in the remote management of Parkinson's disease (PD). Background There is a movement in Parkinson's care from a clinic-based model 1 to P4 medicine, meaning medicine that is predictive, preventive, personalised and participatory.
WED 131 EVALUATING THE CLINICAL UTILITY OF THE PARKINSON'S KINETIGRAPH (PKG)
Objective To evaluate the utility of the Parkinson's Kinetigraph (PKG™) in the remote management of Parkinson's disease (PD). Background There is a movement in Parkinson's care from a clinic-based model 1 to P4 medicine, meaning medicine that is predictive, preventive, personalised and participatory. 2 The development of wearable technology provides an opportunity to monitor patients remotely, and deliver targeted care. The PKG™ is a wrist-worn device that objectively measures Parkinson's symptoms. Aim To evaluate the utility of the PKG™ in managing PD patients remotely, and the perception of service users. Method PKG™ data were collated in real time. Patient acceptability data were collated via a patient questionnaire (n=61). Results Between July 2015 and January 2018, 216 PKGs were performed. A variety of symptoms were identified, including different types of 'OFF' times (wearing off (25%), delayed on (6%) no drug response (8%)) and non-motor complications (fragmented sleep (33%) and daytime somnolence (21%)), with subsequent treatment recommendations being made. Patient acceptability of the PKG™ was high, 81% of patients being satisfied not having to travel for clinic appointments. Conclusions The PKG™ facilitated remote treatment recommendations. Remote management was acceptable to patients. Future evaluations will evaluate patient outcome.
Neuroschistosomiasis is an under-recognised complication of one of the world's most prevalent, yet neglected parasitic diseases, which if left untreated can result in severe disability. Although schistosomiasis is most commonly found in the tropics, neurologists in developed countries must have a low index of suspicion in the appropriate clinical setting.
We describe a 17 year old previously fit and well Guinean lady presenting with subacute, progressive, symmetric lower limb hyperaesthesia and urinary retention. Neurological examination was consistent with a myeloradiculopathy. Initial tests revealed an eosinophilia and raised ESR. CSF and imaging findings supported the clinical diagnosis of myeloradiculopathy secondary to schistosomiasis. She responded well to empirical steroids and praziquantel with complete resolution of sensory and urinary symptoms over several weeks. Serology later confirmed the diagnosis.
Transverse myelitis and myeloradiculopathy affecting the conus medullaris and/or cauda equina are the most common presentations associated with neuroschistosomiasis. Symptoms are principally due to an inflammatory response to the retained schistosome eggs. This case details the differential diagnosis of a subacute myeloradiculopathy and highlights the importance of a thorough travel history. In the appropriate clinical context, neuroschistosomiasis should be included in the differential diagnosis of a subacute myeloradiculopathy, enabling prompt diagnosis and optimal management. A 26-year-old Bolivian man presented with a 3 year history of occipital headaches and bilateral papilloedema. MRI showed communicating hydrocephalus and leptomeningeal enhancement. CSF analysis revealed an opening pressure of 32cmH 2 O, lymphocytic pleocytosis, protein 1.9 g/dL and CSF glucose 0.4 mmol/L. CSF AFB, bacterial and fungal culture, TB-PCR, 18S rDNA PCR, serum b-d glucan, and HIV were all negative. Serum ACE was normal. Steroids and methotrexate were commenced for probable neurosarcoidosis.
He had readmissions with recurrent headache, meningism, symptoms of raised intracranial pressure and development of limb spasticity and brisk reflexes. Repeat imaging demonstrated stable hydrocephalus. Despite immunosuppression and empirical TB treatment, he remained symptomatic with a persistently active CSF: maximum opening pressure 36cmH 2 O, protein 3.9 g/dL, WCC 205 lymphocytes and low CSF-toserum glucose ratio on repeated therapeutic LPs. 
